Search for a command to run...
Promoter and Institution shareholding in Fredun Pharmaceuticals has declined YoY, contrasting with the sector averages where no changes have occurred.
Public shareholding increased slightly, indicating retail interest, but overall sentiment remains negative among smart money.
The best-performing stock in the sector, Sudarshan, saw significant institutional buying, highlighting a divergence in performance compared to Fredun Pharmaceuticals.
| Category | Trend | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|
1Promoter4 | 49.32% | 49.15% | 49.16% | 49.16% | 48.93% | 48.93% | 48.93% | 48.93% | |
2Institution1 | 1.6% | 1.6% | 1.6% | 1.6% | 1.59% | 1.59% | 1.59% | 1.59% | |
3Public4 | 8.49% | 8.39% | 8.52% | 8.6% | 8.29% | 7.82% | 8.75% | 8.78% |